Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting

1 Northern Institute for Cancer Research, Newcastle upon Tyne 2 Birmingham Children’s Hospital, Birmingham 3 Southmead Hospital, Bristol 4 The Royal London Hospital, London 5 Yorkhill Children’s Hospital, Glasgow 6 Sheffield Children’s Hospital, Sheffield 7 UK NEQAS for Leucocyte Immunophenotyping,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Haematologica (Roma) 2009-06, Vol.94 (6), p.870-874
Hauptverfasser: Irving, Julie, Jesson, Jenny, Virgo, Paul, Case, Marian, Minto, Lynne, Eyre, Lisa, Noel, Nigel, Johansson, Ulrika, Macey, Marion, Knotts, Linda, Helliwell, Margaret, Davies, Paul, Whitby, Liam, Barnett, David, Hancock, Jeremy, Goulden, Nick, Lawson, Sarah, on behalf of UKALL Flow MRD group and UK MRD steering group
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:1 Northern Institute for Cancer Research, Newcastle upon Tyne 2 Birmingham Children’s Hospital, Birmingham 3 Southmead Hospital, Bristol 4 The Royal London Hospital, London 5 Yorkhill Children’s Hospital, Glasgow 6 Sheffield Children’s Hospital, Sheffield 7 UK NEQAS for Leucocyte Immunophenotyping, Royal Hallamshire Hospital, Sheffield 8 Great Ormond Street Children’s Hospital, London, UK Correspondence: Julie Irving, Northern Institute for Cancer Research, Paul O’Gorman Building, Framlington Place, Newcastle upon Tyne, Tyne and Wear, UK, NE2 4HH. E-mail. j.a.e.irving{at}ncl.ac.uk ABSTRACT Minimal residual disease detection, used for clinical management of children with acute lymphoblastic leukemia, can be performed by molecular analysis of antigen-receptor gene rearrangements or by flow cytometric analysis of aberrant immunophenotypes. For flow minimal residual disease to be incorporated into larger national and international trials, a quality assured, standardized method is needed which can be performed in a multi-center setting. We report a four color, flow cytometric protocol established and validated by the UK acute lymphoblastic leukemia Flow minimal residual disease group. Quality assurance testing gave high inter-laboratory agreement with no values differing from a median consensus value by more than one point on a logarithmic scale. Prospective screening of B-ALL patients (n=206) showed the method was applicable to 88.3% of patients. The minimal residual disease in bone marrow aspirates was quantified and compared to molecular data. The combined risk category concordance (minimal residual disease levels above or below 0.01%) was 86% (n=134). Thus, this standardized protocol is highly reproducible between laboratories, sensitive, applicable, and shows good concordance with molecular-based analysis. Key words: childhood acute lymphoblastic leukemia, minimal residual disease, flow cytometry. Related Article Bridging the gap between the north and south of the world: the case of treatment response in childhood acute lymphoblastic leukemia Martin Stanulla, André Schrauder Haematologica 2009 94: 748-752. [Full Text] [PDF]
ISSN:0390-6078
1592-8721
DOI:10.3324/haematol.2008.000414